drug prices

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen Inc. (NASDAQ: AMGN) heads into the Christmas-shortened trading week with a fresh wave of policy headlines, a newly expanded FDA label win in rare disease, and a market still laser-focused on what comes next for its obesity pipeline. Shares

21 December 2025

Healthcare Stocks Outlook (Dec. 21, 2025): Drug-Price Deals, ACA Premium Shock, and 2026 Catalysts Investors Are Watching

Sunday, December 21, 2025 — With U.S. markets heading into a holiday-shortened final trading stretch, healthcare stocks are back in focus as investors weigh a year-end “Santa rally” against a fast-moving policy backdrop that is unusually direct for the sector:

21 December 2025

ACA · Drug Pricing · Healthcare Stocks · Investment Strategies · Market Outlook

Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

December 20, 2025 — Amgen Inc. (NASDAQ: AMGN) is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA

20 December 2025

Dividend Updates · FDA Approvals · Investment Analysis · NASDAQ:AMGN · Pharmaceuticals · Stock Market News

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson (NYSE: JNJ) is back on investors’ radar on Friday, December 19, 2025, as Wall Street digests a fast-moving mix of Washington drug-pricing headlines, a string of U.S. FDA decisions across pharma and medtech, ongoing talc litigation, and

19 December 2025

Drug Pricing · FDA Updates · Investment News · Pharma Industry · Stock Market

GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK plc (LSE/NYSE: GSK) is in the spotlight today as U.S. Medicare unveils steep price cuts on key respiratory drugs, analysts lift their price targets, and regulators publish fresh details on the company’s ongoing share buyback programme. Here’s a complete,

26 November 2025

Company Updates · Healthcare News · Medicare · Pharma · Stock Market

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the

1 November 2025

Business News · Healthcare Investments · NYSE:PFE · Pfizer · Pharma Industry · Stock Market

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Stock Price & Recent Performance Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlier ts2.tech – as investors grappled with

30 October 2025

Drug Pricing · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market · Trump Administration

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow

30 September 2025

Healthcare · NYSE:PFE · Pharmaceuticals · Policy · Politics · US News

Trump’s Tariff Tsunami: 100% Drug Tax and New Import Levies Rock Global Trade

Trump’s New Tariff Salvo: Drugs, Trucks and Cabinets Under Fire In a dramatic escalation of his trade war, President Donald Trump on Thursday unveiled a new wave of tariffs targeting pharmaceuticals, trucks, and home furnishings. In a Truth Social post

26 September 2025

Economics · International Relations · NASDAQ:PCAR · Politics · Trade · US Policy